Laurie Stelzer
CIK 1644348 · Chief Financial Officer · last filed 2026-06-05
Laurie Stelzer is a Chief Financial Officer who has filed 48 SEC Form 4 insider transactions across 9 companies since 2015. The most recent filing, for PMVP, was dated Jun 5, 2026. Across all open-market trades the lifetime net is +$172.6K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
9
48
$172.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PMVP | Director | — | $1.11 | — | $0 | 6 | 2026-06-05 |
| MBX | Director | — | $35.51 | — | $0 | 2 | 2026-06-05 |
| SYRE | Director | — | $80.79 | — | $0 | 3 | 2026-05-29 |
| SION | Director | — | $35.92 | — | $0 | 1 | 2025-06-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Financial Officer | 102,312 | $58.70 | $6.01M | -$172.2K | 4 | 2023-08-10 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 4 | 2022-06-10 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | EVP & Chief Financial Officer | 28,122 | $99.99 | $2.81M | $0 | 5 | 2022-03-11 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP, Chief Financial Officer | 126,167 | — | — | $344.8K | 22 | 2020-02-24 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | MBX | Grant (A) | — | $0 | EDGAR |
| 2026-05-29 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2026-01-22 | MBX | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | SION | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2024-05-16 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2023-11-27 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |